Parsabiv (Etelcalcetide) For The Treatment Of Secondary Hyperparathyroidism (SHPT) In Dialysis Patients
Parsabiv (Etelcalcetide), an innovative calcimimetic, was recently formally approved for the treatment of secondary hyperparathyroidism…
News
Retevmo (Selpercatinib) Achieves Positive Results in Phase III Clinical Trial
August 5, 2023 – Eli Lilly and Company (Eli Lilly) announced that its RET inhibitor…
Isturisa(Osilodrostat): New Hope For Cushing’s Syndrome Treatment
Cushing’s syndrome is a rare disease caused by the overproduction of cortisol from the adrenal…
Actimmune (Interferon Gamma-1b) Gains Expanded Approval For Severe Osteopetrosis In Pediatric Patients
March 29, 2025 – Horizon Therapeutics, the manufacturer of Actimmune® (interferon gamma-1b), has announced that the U.S.…
Augtyro (Repotrectinib) Capsules: What Patients Really Want to Know
If you or a loved one has been prescribed Augtyro Repotrectinib for non-small cell lung…
Lorviqua (Lorlatinib) Approved In EU For First-Line Treatment Of ALK-Positive Non-Small Cell Lung Cancer
Pfizer Inc. recently announced that its third-generation anaplastic lymphoma kinase (ALK) inhibitor Lorviqua (generic name:…
BETAGRIN Announces Revolutionary New Energy Solution To Lead The Future Of Green Technology
[Global, October 15, 2023] – Today, BETAGRIN, a leading global green technology company, officially announced…
Golidocitinib Capsules: A breakthrough In A New Generation Of JAK1 Inhibitors
Among the latest advances in the pharmaceutical field, Golidocitinib Capsules, a new generation of JAK1…
FDA Accelerates Approval Of TALVEY™ (Talquetamab-tgvs) For The Treatment Of Multiple Myeloma
On 9 August 2023, the US Food and Drug Administration (FDA) announced the accelerated approval…
Astellas Pharmaceuticals Group: Driven By Innovation
March 19, 2025 – Astellas Pharma Group (TSE: 4503) continues to demonstrate its innovative strength…
Copyright@ 2016-2024 Hong Kong Deng Yue Med Al Rights